[HTML][HTML] Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non …
R Saito, S Sugawara, R Ko, K Azuma, R Morita… - European Journal of …, 2023 - Elsevier
Background This multicenter phase 2 trial evaluated the safety and efficacy of osimertinib
and platinum-based chemotherapy (OPP) in patients with previously untreated EGFR …
and platinum-based chemotherapy (OPP) in patients with previously untreated EGFR …
First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study
M Lorenzi, A Ferro, F Cecere, D Scattolin… - The …, 2022 - academic.oup.com
Background Osimertinib became the standard treatment for patients with untreated EGFR-
mutant advanced non-small cell lung cancer (aNSCLC) following results reported in the …
mutant advanced non-small cell lung cancer (aNSCLC) following results reported in the …
[HTML][HTML] Osimertinib plus platinum–pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung …
D Planchard, PH Feng, N Karaseva, SW Kim, TM Kim… - ESMO open, 2021 - Elsevier
Background The phase III FLAURA2 (NCT04035486) study will evaluate efficacy and safety
of first-line osimertinib with platinum–pemetrexed chemotherapy versus osimertinib …
of first-line osimertinib with platinum–pemetrexed chemotherapy versus osimertinib …
[HTML][HTML] Osimertinib in untreated epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer
V Gregorc, C Lazzari, N Karachaliou… - … lung cancer research, 2018 - ncbi.nlm.nih.gov
© Translational lung cancer research. All rights reserved. Transl Lung Cancer Res 2018; 7
(Suppl 2): S165-S170 tlcr. amegroups. com the mechanisms of acquired resistance to EGFR …
(Suppl 2): S165-S170 tlcr. amegroups. com the mechanisms of acquired resistance to EGFR …
Efficacy of osimertinib plus bevacizumab vs osimertinib in patients with EGFR T790M–mutated non–small cell lung cancer previously treated with epidermal growth …
H Akamatsu, Y Toi, H Hayashi, D Fujimoto… - JAMA …, 2021 - jamanetwork.com
Importance Although treatment with first-generation epidermal growth factor receptor (EGFR)–
tyrosine kinase inhibitor (TKI) plus antiangiogenic inhibitor has shown promising efficacies …
tyrosine kinase inhibitor (TKI) plus antiangiogenic inhibitor has shown promising efficacies …
A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non–Small-cell Lung Cancer: The OPAL Study …
H Asahina, K Tanaka, S Morita, M Maemondo… - Clinical Lung Cancer, 2021 - Elsevier
Background Osimertinib, a third-generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor, is now a standard treatment of previously untreated EGFR-mutated …
tyrosine kinase inhibitor, is now a standard treatment of previously untreated EGFR-mutated …
[HTML][HTML] Osimertinib versus osimertinib plus chemotherapy for non–small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment …
K Tanaka, H Asahina, J Kishimoto, Y Miyata… - European Journal of …, 2021 - Elsevier
Background Osimertinib is now a standard treatment for patients with previously untreated
EGFR-mutated advanced non–small cell lung cancer (NSCLC). We here investigated …
EGFR-mutated advanced non–small cell lung cancer (NSCLC). We here investigated …
A real world analysis of first line treatment of advanced EGFR mutated non-small cell lung cancer: A multi-center, retrospective study
CS Lee, I Ahmed, E Miao, S Chung… - Journal of Oncology …, 2022 - journals.sagepub.com
Introduction The recently published FLAURA trial demonstrated that osimertinib has
remarkable efficacy in front-line setting for non-small cell lung cancer (NSCLC). While this …
remarkable efficacy in front-line setting for non-small cell lung cancer (NSCLC). While this …
Postprogression outcomes for osimertinib versus standard-of-care egfr-tki in patients with previously untreated egfr-mutated advanced non–small cell lung cancer
D Planchard, MJ Boyer, JS Lee, A Dechaphunkul… - Clinical Cancer …, 2019 - AACR
Purpose: In the phase III FLAURA study, third-generation epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor (TKI) osimertinib significantly improved progression-free …
(EGFR) tyrosine kinase inhibitor (TKI) osimertinib significantly improved progression-free …
Overall survival (OS) in patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC) treated with osimertinib: results from two phase II …
T Mitsudomi, MJ Ahn, L Bazhenova… - Annals of …, 2017 - annalsofoncology.org
Background: Osimertinib is an oral, potent, CNS active, irreversible EGFR-TKI approved to
treat pts with T790M-positive advanced NSCLC. Here we present updated data from a pre …
treat pts with T790M-positive advanced NSCLC. Here we present updated data from a pre …